Edmund Yao, MD
Internal Medicine · Los Angeles, CANPI 1245328004
Payments from drug & device makers
Across 312 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$776
- Sunovion Pharmaceuticals Inc.$534
- UCB, Inc.$362
- Johnson & Johnson$294
- Novo Nordisk$281
- GSK$247
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,51098%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $776 |
| Sunovion Pharmaceuticals Inc. | 42 | $534 |
| UCB, Inc. | 17 | $362 |
| Johnson & Johnson | 31 | $294 |
| Novo Nordisk | 18 | $281 |
| GSK | 13 | $247 |
| Vanda Pharmaceuticals Inc. | 22 | $245 |
| AstraZeneca | 8 | $196 |
| Astellas Pharma US Inc | 7 | $178 |
| Novartis | 9 | $166 |
| Sumitomo Pharma America, Inc. | 14 | $125 |
| Pfizer | 7 | $118 |
| Bayer | 5 | $97 |
| Lilly USA, LLC | 5 | $82 |
| Acadia Pharmaceuticals Inc | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $76 |
| Avanir Pharmaceuticals, Inc. | 5 | $74 |
| Boehringer Ingelheim | 4 | $70 |
| Corcept Therapeutics | 4 | $63 |
| Vivus LLC | 2 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Eisai Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 3 | $37 |
| Merck | 3 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Mylan Specialty L.p. | 2 | $31 |
| SK Life Science, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| Amgen | 1 | $19 |
| Medtronic | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $3 |
How this compares
$4,599 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $282,115 |
| JardianceEmpagliflozin | 323 | $221,258 |
| JanuviaSitagliptin Phosphate | 278 | $204,022 |
| LinzessLinaclotide | 325 | $186,566 |
| EliquisApixaban | 305 | $158,149 |
| RybelsusSemaglutide | 83 | $98,219 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $90,703 |
| TrulicityDulaglutide | 150 | $85,697 |
| XareltoRivaroxaban | 205 | $81,646 |
| IngrezzaValbenazine Tosylate | 19 | $77,758 |
| TradjentaLinagliptin | 144 | $70,884 |
| FarxigaDapagliflozin Propanediol | 126 | $62,010 |
| RexultiBrexpiprazole | 41 | $49,058 |
| XifaxanRifaximin | 23 | $47,781 |
| Lacosamide | 353 | $45,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $281 | $407,943383 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $70 | $305,146485 claims |
| AbbVieLinzess, Viberzi, Ubrelvy | $776 | $239,579351 claims |
| MerckJanuvia, Janumet | $35 | $222,341307 claims |
| PfizerEliquis | $118 | $158,149305 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $247 | $118,267192 claims |
| Johnson & JohnsonXarelto, Invokana | $294 | $106,634240 claims |
| Lilly USA, LLCTrulicity | $82 | $85,697150 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $196 | $78,338152 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $31 | $77,75819 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $49,05841 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $76 | $47,78123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.